Computed tomography dose optimisation in cystic fibrosis: A review.
O'Neill, Siobhán B.
Murphy, Kevin P.
O'Connor, Owen J.
Maher, Michael M.
Baishideng Publishing Group
Cystic fibrosis (CF) is the most common autosomal recessive disease of the Caucasian population worldwide, with respiratory disease remaining the most relevant source of morbidity and mortality. Computed tomography (CT) is frequently used for monitoring disease complications and progression. Over the last fifteen years there has been a six-fold increase in the use of CT, which has lead to a growing concern in relation to cumulative radiation exposure. The challenge to the medical profession is to identify dose reduction strategies that meet acceptable image quality, but fulfil the requirements of a diagnostic quality CT. Dose-optimisation, particularly in CT, is essential as it reduces the chances of patients receiving cumulative radiation doses in excess of 100 mSv, a dose deemed significant by the United Nations Scientific Committee on the Effects of Atomic Radiation. This review article explores the current trends in imaging in CF with particular emphasis on new developments in dose optimisation.
Cystic fibrosis , Dose optimization , Computed tomography , Dose , Ionising radiation , Kalydeco , low dose CT , CT dose reduction
Ferris, H., Twomey, M., Moloney, F., O’Neill, S. B., Murphy, K. P., O’Connor, O. J. and Maher, M. M. (2016) 'Computed tomography dose optimisation in cystic fibrosis: A review', World Journal of Radiology: WJR, 8(4) pp. 331-341. doi:10.4329/wjr.v8.i4.331
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/